What an interventional cardiologist should know about the pharmacological treatment of acute myocardial infarction

Related Experiment Video

Updated: Aug 8, 2026

Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice
07:28

Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice

Published on: July 2, 2018

F W Verheugt1

  • 1Department of Cardiology, Heartcenter, University Hospital Nijmegen, The Netherlands. f.verheugt@cardio.azn.nl

Seminars in Interventional Cardiology : SIIC
|July 16, 1999
PubMed

Insights

Antithrombotic therapy for acute myocardial infarction impacts coronary procedures. Antiplatelet therapy is recommended post-angioplasty due to manageable bleeding and no procoagulant effects.

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Acute myocardial infarction (AMI) treatment involves pain relief, anti-ischaemic drugs, and antithrombotic therapy.
  • Antithrombotic therapy in AMI presents challenges for coronary procedures due to bleeding risks and potential procoagulant effects.

Purpose of the Study:

  • To evaluate the implications of antithrombotic therapy on coronary procedures during acute myocardial infarction.
  • To determine optimal post-angioplasty antithrombotic strategies in AMI.

Main Methods:

  • Review of antithrombotic agents used in AMI treatment.
  • Analysis of bleeding complications and procoagulant effects of various antithrombotic therapies.
  • Assessment of impact on coronary procedures and post-angioplasty management.

Main Results:

  • Antiplatelet therapy offers manageable bleeding complications without procoagulant effects.
  • Antithrombin therapy exhibits unpredictable rebound effects.
  • Thrombolytic therapy can have procoagulant effects, potentially complicating early coronary procedures.

Conclusions:

  • Antiplatelet therapy is suitable for post-angioplasty management in AMI due to its favorable safety profile.
  • Careful consideration of antithrombotic agent choice is crucial for managing AMI patients undergoing coronary procedures.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...